Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Cash from Financing Activities (2022 - 2025)

Axsome Therapeutics' Cash from Financing Activities history spans 4 years, with the latest figure at $16.4 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 15.03% year-over-year to $16.4 million; the TTM value through Dec 2025 reached $101.5 million, up 75.42%, while the annual FY2025 figure was $101.5 million, 75.42% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was $16.4 million at Axsome Therapeutics, down from $21.3 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $246.1 million in Q2 2023 and bottomed at -$1.2 million in Q1 2024.
  • The 4-year median for Cash from Financing Activities is $29.8 million (2024), against an average of $48.4 million.
  • The largest YoY upside for Cash from Financing Activities was 712300.0% in 2024 against a maximum downside of 102.3% in 2024.
  • A 4-year view of Cash from Financing Activities shows it stood at $1.1 million in 2022, then crashed by 100.19% to -$2000.0 in 2023, then soared by 712300.0% to $14.2 million in 2024, then rose by 15.03% to $16.4 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Cash from Financing Activities are $16.4 million (Q4 2025), $21.3 million (Q3 2025), and $34.5 million (Q2 2025).